Search Results
Your search for The matches 34841 pages
Showing 5651 - 5700Addition of PD-1 Inhibitor Serplulimab to Chemotherapy in the First-Line Treatment of Extensive-Stage SCLC
As reported in JAMA by Cheng et al, an interim analysis of the phase III ASTRUM-005 trial has shown that the addition of the PD-1 inhibitor serplulimab to chemotherapy improved overall survival in the first-line treatment of patients with extensive-stage small cell lung cancer (SCLC). Study ...
New Study Highlights Sexual Problems Among Young Women Who Have Had Cancer
Young women who are cancer survivors may be at a much higher risk of sexual problems, including loss of libido and discomfort, according to research published by Wettergren et al in the journal Acta Oncologica. The study also suggests that cancer type and intensity of treatment may influence the...
Transportation Barriers Among Cancer Survivors: Effect on ER Use and Mortality
New research showed that cancer survivors who delayed care due to a lack of transportation were more likely to use the emergency room (ER), according to the study published by Jiang et al in the Journal of Clinical Oncology. They also had the highest risks of all-cause and cancer-specific...
Is Mortgage Discrimination Adversely Associated With Receipt of Guideline-Concordant NSCLC Care?
Findings reported by researchers from the American Cancer Society (ACS) and Johns Hopkins University showed that area-level mortgage discrimination may be adversely associated with receipt of guideline-concordant care among patients with non–small cell lung cancer (NSCLC) in the United States,...
Adjuvant Nivolumab/Ipilimumab vs Nivolumab in Resected Stage IIIB–D or IV Melanoma
As reported in the Journal of Clinical Oncology by Jeffrey S. Weber, MD, PhD, and colleagues, the phase III CheckMate 915 trial showed no improvement in recurrence-free survival with adjuvant nivolumab/ipilimumab vs nivolumab in patients with resected stage IIIB–D or IV melanoma. Study Details In...
Symptom Clusters in Adult Survivors of Childhood Cancer
In a report from the St. Jude Lifetime Cohort Study population reported in the Journal of Clinical Oncology, Shin et al identified symptom clusters among adult survivors of childhood cancer and potential associations with health-related quality of life and physical and neurocognitive performance....
Single vs Multiple Doses of Prophylactic IV Antibiotics to Prevent Surgical Site Infection in Implant-Based Breast Reconstruction
In a Swedish study reported in JAMA Network Open, Gahm et al found that multiple vs single doses of prophylactic intravenous (IV) antibiotics did not significantly reduce the risk of surgical site infection leading to implant removal in women undergoing implant-based breast reconstruction after...
Christopher E. Jensen, MD, on Older Adults With AML: A Price Paid for High-Intensity Chemotherapy?
Christopher E. Jensen, MD, of the University of North Carolina School of Medicine, talks about older adults with acute myeloid leukemia who receive high-intensity chemotherapy. Although they may live longer, much of their survival gains may be spent engaged in oncology care (Abstract 376).
Study Investigates Potential Embryonic Origin of Medulloblastomas
Medulloblastomas may exist in a premalignant form at birth after initially developing during the first or second trimester of pregnancy, according to a new international study published by Hendrikse et al in Nature. As medulloblastomas typically present around age 7, the team’s discovery is the...
Research Examines a New Tool for Discovering Cancer-Driving Structural Variations
An advanced software tool for analyzing DNA sequences from tumor samples has uncovered new, likely cancer-driving genes. In a study, Weill Cornell Medicine researchers designed the software, known as CSVDriver, to map and analyze the locations of large mutations, known as structural variants, in...
GPRC5D-Targeted CAR T-Cell Therapy in Heavily Pretreated Patients With Multiple Myeloma
In a single-institution phase I study reported in The New England Journal of Medicine, Sham Mailankody, MBBS, and colleagues found that chimeric antigen receptor (CAR) T cells targeting G protein–coupled receptor, class C, group 5, member D (GPRC5D) were active in heavily pretreated patients with...
Minimally Invasive vs Open Nephrectomy for Kidney Cancer: 1-Year Health-Care Expenditure and Utilization
In a retrospective cohort study reported in JAMA Network Open, Okhawere et al found that minimally invasive surgery was associated with similar or reduced total expenditures vs open surgery during the first year after partial or radical nephrectomy for kidney cancer. Study Details The study...
Oncologist Use of Reduced Doses of New Systemic Treatments in Patients With Metastatic Cancer
In a survey study reported in JCO Oncology Practice, Jimenez et al found that half of surveyed oncologists reported sometimes or usually using reduced doses at initiation of a new systemic treatment in patients with metastatic cancer in order to potentially reduce toxicity. Study Details The study...
Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
In a single-institution study reported in JAMA Oncology, Allen S. Ho, MD, and colleagues found evidence that active surveillance may be a suitable treatment for most patients with low-risk papillary thyroid carcinoma. Study Details The prospective study included 222 patients enrolled at...
IASLC Names Co-Chairs of the 2023 World Conference on Lung Cancer
Three thoracic oncologists were named co-chairs of the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC), which will take place September 9–12 in Singapore. Co-chairs work with IASLC to plan the annual research meeting, select program track...
Real-World Experience With Durvalumab at the Mayo Clinic Mirrors PACIFIC Trial Findings
Concurrent chemoradiation therapy followed by durvalumab has become the standard of care in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC), based on the PACIFIC trial.1 However, clinical trials have predetermined inclusion and exclusion criteria, and they evaluate...
Real-World Evidence Confirms Survival Benefit of Durvalumab in Locally Advanced Non–Small Cell Lung Cancer
In locally advanced non–small cell lung cancer (NSCLC), immunotherapy consolidation with the PD-L1 inhibitor durvalumab improved overall survival in the PACIFIC trial,1 thus leading to its use after chemoradiotherapy as a standard of care. Real-world evidence of durvalumab’s effect on overall and...
Expert Point of View: Jacek Jassem, MD
Abstract discussant Jacek Jassem, MD, of the Medical University of Gdansk, Poland, underscored smoking as the most important cause of lung cancer, noting that between 85% and 90% of patients with lung cancer are current or former smokers. “Lung cancer screening, which has recently become standard...
Expert Point of View: Benjamin Besse, MD, PhD
Discussant of the IMpower010 abstract, Benjamin Besse, MD, PhD, Professor and Head of Clinical Research at Institute Gustave Roussy, Villejuif, France, said there is enough evidence to use adjuvant immunotherapy in stage II–IIIA resected non–small cell lung cancer (NSCLC), calling the increased...
Study Finds High-Intensity Intervention Helped One-Third of Participants in Lung Cancer Screening Program to Quit Smoking
Despite significant advancements in cancer therapy, the number-one stopper of lung cancer remains the most basic intervention: quitting smoking. Unfortunately, for long-term smokers, that intervention can sometimes be the most challenging. According to data presented during the International...
IMpower010: Early Survival Data Favor Atezolizumab Over Best Supportive Care in Resected NSCLC With PD-L1 Expression ≥ 50%
Early results from the IMpower010 trial showed an overall survival trend favoring adjuvant atezolizumab vs best supportive care for patients with PD-L1–positive (tumor expression ≥ 1%), stage II–IIIA (UICC/AJCC staging system, 7th ed), resected non–small cell lung cancer (NSCLC). These data were...
Highlights From the IASLC 2022 World Conference on Lung Cancer
Over the past few years, we have seen rapid and dramatic transformation in the therapeutic landscape of non–small cell lung cancer (NSCLC). We have had multiple new targeted therapies for newer targets (previously undruggable targets) and better diagnostic strategies to workup patients to realize...
Expert Point of View: Anand Devaraj, MD, PhD
Abstract discussant Anand Devaraj, MD, PhD, Professor in Thoracic Radiology at Royal Brompton and Harefield Hospitals, and Professor of Thoracic Radiology at the National Heart and Lung Institute, Imperial College London, highlighted the increased risk of second primary tumors among current...
National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
Approximately 6% of patients with stage I to III lung cancer develop second primary lung cancer within 5 years of their initial diagnosis, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer.1 Analysis of data...
Expert Point of View: Anand Devaraj, MD, PhD
Abstract discussant Anand Devaraj, MD, PhD, a thoracic radiologist at Royal Brompton and Harefield hospitals, and Professor of Thoracic Radiology at the National Heart and Lung Institute, Imperial College London, noted that both the Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON) trial...
NELSON vs NLST: Nodule Management Based on Volumetry Shows Increased Benefits
Lung cancer screening has been shown to significantly reduce lung cancer mortality, but some management protocols have more benefit than others, according to data presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer (WCLC).1 Although the...
DART Trial: Concurrent Radiotherapy Plus Durvalumab Active in Older Patients With Locally Advanced Lung Cancer
Interim results of a phase II study have demonstrated the safety and feasibility of treating elderly and frail patients with locally advanced non–small cell lung cancer (NSCLC) with the monoclonal antibody durvalumab during and after radiation therapy, without chemotherapy. The results of a...
Expert Point of View: Corinne Faivre-Finn, MD, PhD, and Masahiro Tsuboi, MD
The first discussant of the NADIM II study, Corinne Faivre-Finn, MD, PhD, Professor of Thoracic Radiation Oncology, University of Manchester, and Honorary Consultant Clinical Oncologist at The Christie NHS Foundation Trust, Manchester, England, called the results “very impressive” but noted that...
NADIM II Trial: Neoadjuvant Chemoimmunotherapy Improved Survival in Resectable, Stage IIIA NSCLC
In patients with resectable, stage IIIA non–small cell lung cancer (NSCLC), the addition of neoadjuvant nivolumab to platinum-based chemotherapy significantly improved overall survival compared with neoadjuvant chemotherapy alone, according to data presented by Mariano Provencio, MD, PhD, at the...
Expert Point of View: Chia Puey Ling, MBBS, MMed, MRCP, FRACP, PhD
Discussant of the exploratory analysis of the POSEIDON trial, Chia Puey Ling, MBBS, MMed, MRCP, FRACP, PhD, a medical oncologist at Tan Tock Seng Hospital, Singapore, noted that although 30% of the mutation-evaluable population had KRAS mutations, only a small percentage of patients had co-mutated...
Exploratory Analysis of POSEIDON: Chemoimmunotherapy Regimen May Offer Survival Benefit in Subgroups of Patients With Metastatic NSCLC
The addition of the CTLA-4 inhibitor tremelimumab to durvalumab and chemotherapy in the first-line setting has already demonstrated an overall survival and progression-free survival benefit vs chemotherapy alone in patients with metastatic non–small cell lung cancer (NSCLC). According to data...
Dawn L. Hershman, MD, on Prophylactic Colony Stimulating Factors for Neutropenia: Improving Clinicians’ Prescribing Practices
Dawn L. Hershman, MD, of Columbia University College of Physicians and Surgeons, discusses findings that showed substantial variability in clinicians’ adherence to prescribing primary prophylactic colony stimulating factors in a pragmatic trial. Although the ability to opt out of the intervention...
Justin M. Barnes, MD, on Medicaid Expansion and Changes in Cancer Mortality Rates
Justin M. Barnes, MD, of the Washington University School of Medicine, discusses the ways in which Medicaid expansion under the Affordable Care Act seems to affect distant diagnoses and cancer deaths per year, the differences in the impact of expansion between Black and White patients in the United ...
Barbara Eichhorst, MD, on CLL: Venetoclax and Obinutuzumab With or Without Ibrutinib vs Chemoimmunotherapy
Barbara Eichhorst, MD, of the German CLL Study Group and the University of Cologne, discusses phase III findings from the GAIA/CLL13 trial, which showed that time-limited treatment with venetoclax, obinutzumab, and ibrutinib or venetoclax plus obinutzumab improved progression-free survival compared ...
Highlights From the 2022 ASCO Quality Care Symposium
The 2022 ASCO Quality Care Symposium took place in Chicago over the weekend. On this episode, we’re featuring two speakers who presented data at the meeting: the first focuses on the effects of Medicaid expansion on cancer mortality rates, and the second describes efforts to improve prescribing...
John B.A.G. Haanen, MD, PhD, on Melanoma: Phase III Data on Treatment With Tumor-Infiltrating Lymphocytes vs Ipilimumab
John B.A.G. Haanen, MD, PhD, of The Netherlands Cancer Institute, discusses recent phase III findings, which show that tumor-infiltrating lymphocytes (TILs) improve progression-free survival compared with ipilimumab by 50% in patients with advanced melanoma after not responding to anti–PD-1...
Study Focuses on Molecular Details of Precancerous Clonal Outgrowth in Blood Cells
A common, spontaneous mutation in blood stem cells, which has been linked to a higher risk of blood cancer and cardiovascular disease, may promote these diseases by altering the stem cells’ programming of gene activity and the mix of blood cells they produce, according to a study co-led by...
Researchers Identify Potential Biomarker to Distinguish Group 3 and Group 4 Medulloblastomas
It may soon be possible to identify group 4 medulloblastomas from more aggressive group 3 tumors. Research based on a little-explored part of RNA that creates proteins may lead to the development of better-targeted therapies, according to investigators at the Johns Hopkins Kimmel Cancer Center....
Selpercatinib in RET Fusion–Positive Advanced NSCLC
As reported in the Journal of Clinical Oncology by Alexander Drilon, MD, and colleagues, an updated analysis of the multicohort phase I/II LIBRETTO-001 trial confirmed the activity of selpercatinib in patients with RET fusion–positive advanced non–small cell lung cancer (NSCLC). The trial supported ...
Risks Associated With Sinoatrial Node Radiation Dose in Patients With Lung Cancer Receiving Definitive Chemoradiotherapy
In a Korean single-institution retrospective cohort study reported in JAMA Oncology, Kim et al found that higher sinoatrial node radiation doses were associated with an increased risk of atrial fibrillation and poorer survival in patients with limited-stage small cell lung cancer (SCLC) and locally ...
Extended-Interval vs Standard-Interval Dosing of Single-Agent Pembrolizumab
In a retrospective cohort study performed in U.S. veterans reported in JAMA Oncology, Strohbehn et al found that a minority of patients receiving singe-agent pembrolizumab for cancer received the extended-interval dosing of 400 mg every 6 weeks. Analysis of efficacy measured as the time to...
FDA Grants Accelerated Approval to Futibatinib for Previously Treated Patients With FGFR2-Mutated Cholangiocarcinoma
On September 30, the U.S. Food and Drug Administration (FDA) granted accelerated approval to futibatinib (Lytgobi) for adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or...
Expert Point of View: Jean-Yves Blay, MD, PhD
The invited discussant of the DeFi trial was Jean-Yves Blay, MD, PhD, General Director of the Center Bérard, Lyon, France, and President of Unicancer, the French Federation of Cancer Centers. He called the DeFi study a “rigorous trial” in a “representative population” that “introduces a new class...
DeFi Trial: Novel Gamma Secretase Inhibitor Halts Progression of Desmoid Tumors
Patients with rare desmoid tumors may finally have an effective treatment. A first-in-class gamma secretase inhibitor, nirogacestat, led to an improvement in progression-free survival in the phase III DeFi trial. The results were presented during the Presidential Symposium at the European Society...
Managing the Risk of Thrombosis in Polycythemia Vera
This is Part 1 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series. Stay tuned for future installments in the coming months. In this video, Dr. Prithviraj Bose and Dr. Ruben Mesa discuss how best to manage the risk of thrombosis in patients with polycythemia vera....
Tissue vs ctDNA NGS for Detecting Actionable Alterations in Patients With Advanced Cancer
A large prospective analysis, published by Bayle et al in Annals of Oncology, evaluated differences between tissue and circulating tumor DNA (ctDNA) next-generation sequencing (NGS) with a large cancer gene panel. The investigators compared the impacts of both methods in terms of molecular tumor...
Inflammatory Markers and Clinical Decline After Adjuvant Chemotherapy in Older Women With Breast Cancer
As reported in the Journal of Clinical Oncology by Ji et al, the HOPE study (Hurria Older Patients [HOPE] with Breast Cancer Study) has shown that older women categorized as robust prior to adjuvant chemotherapy are at risk for clinical decline postchemotherapy, with high baseline levels of the...
2-Year Toxicity With Conventional IMRT vs Hypofractionated SBRT for Localized Prostate Cancer
As reported in The Lancet Oncology by Tree et al, an analysis from the phase III PACE-B trial has shown no difference in 2-year genitourinary or gastrointestinal toxicity with conventionally fractionated/moderately hypofractionated intensity-modulated radiotherapy (IMRT) vs highly hypofractionated...
Association of Breast Cancer Recurrence in Patients Achieving pCR With vs Without Residual DCIS After Neoadjuvant Chemotherapy
In a retrospective analysis from the neoadjuvant I-SPY2 trial reported in JAMA Surgery, Osdoit et al found that among patients with breast cancer achieving pathologic complete response (pCR), there were no significant differences in treatment outcomes according to the presence or absence of...
Outcomes After Nonresponse and Relapse in Children and Young Adults Receiving Tisagenlecleucel for B-Cell ALL
In a retrospective study reported in the Journal of Clinical Oncology, Schultz et al found poor survival among children and young adults with lack of response to tisagenlecleucel for B-cell acute lymphoblastic leukemia (ALL). Salvage therapy after relapse was capable of inducing responses, but...
